This suggests that the inhibition of BACH1 can modulate the metabolic profile in resistant cancers such that the OXPHOS pathway is restored, glycolysis is reduced or omitted, cancer growth is halted, and cancer cells are sensitized to therapy. The gene discussed is BACH1; the disease is cancer.